AST-202 / Aptamer Sci, Korea Advanced Institute of Science and Technology - LARVOL DELTA

Pharmacological and Pharmacokinetic Evaluation of AST-202, CD25-Targeted Aptamer Conjugated with Anti-Mitotic MMAE Warhead for the Treatment of Hematological Malignancies (ASH 2024) - "This improvement of stability was found to translate to improved PK profile relative to AST-202(1), resulting in the dramatic increase of AUC and half-life as well as the decreased CL.Cytotoxicity evaluation against a panel of human lymphoma and leukemia cell lines with different CD25-expression level revealed the correlation of the expression level of the target and CD25-negative Daudi and H929 cells (derived from B-cell lymphoma and multiple myeloma, respectively) were not affected in the range of treatment up to 1uM.Comparative in vivo study with subcutaneous xenografts of AST-202 and single MMAE-conjugated aptamer demonstrated CD25-specific tumor targeting and the superior anti-tumor efficacy of AST202 relative to ApDC with a single payload. The following study with a disseminated tumor model showed dramatic extensions of survival in all treatment groups compared with vehicle and non-binding ApDC controls and survival difference between AST-202(1) and AST-202(3) was..."

PK/PD data • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • IL2 • IL2RA

The world's top three cancer societies 'AACR' opens next month… K-Bio gun dispatch (Newsis) - "Curocell will also present the research results of CAR-T treatment for the treatment of T-cell (immune cell) lymphoma....ViGencell is also planning to release animal test data to evaluate the efficacy of antigen-targeting CAR-T. Therapex plans to introduce the preclinical results of 'TRX-221', a candidate for lung cancer treatment....Aptamer Science will present the research results of 'CD25-ApDC Immuno-Oncology'."

Preclinical • Hematological Malignancies • Lung Cancer • Lymphoma • Oncology • Solid Tumor